<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
PACIFIC PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.02 PAR VALUE PER SHARE
- -------------------------------------------------------------------------------
(Title of Class of Securities)
69475 41 02
---------------------------
(CUSIP Number)
December 31, 1998
-------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosure
provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
<PAGE>
CUSIP NO. 69475 41 02 13G
1 NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Lou Weisbach
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
5 SOLE VOTING POWER
NUMBER 942,600
OF SHARES
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
EACH
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 942,600
WITH:
8 SHARED DISPOSITIVE POWER
0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
942,600
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
/ /
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9).
7.5%
12 TYPE OF REPORTING PERSON
IN
Page 2 of 5 Pages
<PAGE>
ONLY THOSE ITEMS AMENDED ARE REPORTED HEREIN
UNLESS OTHERWISE DEFINED, ALL CAPITALIZED TERMS USED HEREIN SHALL
HAVE THE MEANINGS ASSIGNED TO THEM IN THE INITIAL SCHEDULE 13G FILED BY THE
REPORTING PERSON.
This statement constitutes Amendment No. 1 to the Statement on Schedule 13G
filed April 23, 1998 on behalf of Lou Weisbach (the "Reporting Person") in
connection with the beneficial ownership of the Common Stock, $.02 par value
per share (the "Common Stock"), of Pacific Pharmaceuticals, Inc., a Delaware
corporation (the "Company").
OWNERSHIP. Item 4 is hereby amended and restated in its entirety
to read as follows:
(a) Amount Beneficially Owned as of December 31, 1998:
942,600 shares of Common Stock
(b) Percent of Class:
Based on the Issuer's filing on Form 10-K, dated January 12,
1999, there are an aggregate of 12,490,463 shares of Common
Stock issued and outstanding. As of December 31, 1998, the
Reporting Person beneficially owned 942,600 shares of Common
Stock or approximately 7.5% of the aggregate number of shares
of Common Stock issued and outstanding on such date.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 942,600
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 942,600
(iv) shared power to dispose or to direct the disposition of:
0
Page 3 of 5 Pages
<PAGE>
CERTIFICATION. Item 10 is hereby restated in its entirety to read
as follows:
By signing below, I certify that, to the best of my
knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose
or effect.
Page 4 of 5 Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: Effective as of January 1, 1999
/s/ Lou Weisbach
-------------------------------------
Lou Weisbach
Page 5 of 5 Pages
